Your browser doesn't support javascript.
loading
Dynamic alteration and prognostic significance of tumor-associated CD68+ and CD68+ PD-L1- macrophages in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy.
Wu, Jie; Xie, Rui-Yang; Wei, Li-Hui; Cao, Chuan-Zhen; Shang, Bing-Qing; Guan, You-Yan; Shi, Hong-Zhe; Qu, Wang; Li, Yun; Liang, Jing; Zheng, Shan; Zhou, Ai-Ping; Zhou, Xiao-Feng; Shou, Jian-Zhong; Bi, Xin-Gang.
Affiliation
  • Wu J; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Xie RY; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wei LH; Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, China.
  • Cao CZ; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Shang BQ; Department of Urology, China-Japan Friendship Hospital, Beijing, China.
  • Guan YY; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Shi HZ; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Qu W; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Li Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Liang J; Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, China.
  • Zheng S; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhou AP; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhou XF; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Shou JZ; Department of Urology, China-Japan Friendship Hospital, Beijing, China.
  • Bi XG; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cancer Med ; 12(4): 4981-4992, 2023 02.
Article in En | MEDLINE | ID: mdl-36043478
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Neoadjuvant Therapy Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Neoadjuvant Therapy Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: Country of publication: